The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Meridian Bioscience's revenues will increase 11.5% and EPS will shrink 0.0%.
The average estimate for revenue is $47.0 million. On the bottom line, the average EPS estimate is $0.21.
Last quarter, Meridian Bioscience recorded revenue of $47.3 million. GAAP reported sales were 0.1% higher than the prior-year quarter's $47.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.24. GAAP EPS of $0.24 for Q2 were 4.3% higher than the prior-year quarter's $0.23 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 65.0%, 240 basis points better than the prior-year quarter. Operating margin was 32.3%, 50 basis points better than the prior-year quarter. Net margin was 21.7%, 130 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $188.9 million. The average EPS estimate is $0.89.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 456 members out of 466 rating the stock outperform, and 10 members rating it underperform. Among 111 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 109 give Meridian Bioscience a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Meridian Bioscience is hold, with an average price target of $21.00.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Meridian Bioscience. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Meridian Bioscience to My Watchlist.